- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
- Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
- Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
More ▼
Key statistics
On Wednesday, Cyclacel Pharmaceuticals Inc (CYCCP:NAQ) closed at 8.01, 52.57% above the 52 week low of 5.25 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.90 |
---|---|
High | 13.90 |
Low | 7.60 |
Bid | 8.00 |
Offer | 11.29 |
Previous close | 8.01 |
Average volume | 4.00k |
---|---|
Shares outstanding | 1.32m |
Free float | 1.22m |
P/E (TTM) | -- |
Market cap | 3.03m USD |
EPS (TTM) | -26.72 USD |
Annual div (ADY) | 0.600 USD |
---|---|
Annual div yield (ADY) | 4.44% |
Div ex-date | Jan 19 2024 |
Div pay-date | Feb 01 2024 |
Data delayed at least 15 minutes, as of Apr 24 2024 20:53 BST.
More ▼